Is ELV or VRTX cheaper?

On trailing earnings, ELV is cheaper: ELV trades at a 17.19 P/E and VRTX at 26.39.

Which has grown faster, ELV or VRTX?

Over the past five years, VRTX grew revenue faster — ELV at a 9.97% CAGR versus VRTX at 13.82%.

Does ELV or VRTX pay a bigger dividend?

ELV pays a dividend (1.70% yield) while VRTX does not currently pay one.

Is ELV or VRTX more profitable?

VRTX runs the higher net margin — ELV at 2.62% versus VRTX at 35.40%.

Which has been the better investment, ELV or VRTX?

Over the past 10-year, VRTX delivered the higher annualized total return — ELV at 13.43% versus VRTX at 17.13%. Past performance doesn't predict future results.

Elevance Health Inc. (ELV) vs Vertex Pharmaceuticals Incorporated (VRTX)

VRTX leads on 9 of 16 compared metrics, though ELV is the cheaper stock.

A side-by-side comparison of Elevance Health Inc. and Vertex Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 13, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

Vertex Pharmaceuticals Incorporated

$112.92B

$444.93Healthcare

Total return — ELV vs VRTX

growth of $100 · last 25y

ELV +1875.9%VRTX +1750.0%ELV compounded faster

ELV VRTX

ELV vs VRTX: by the numbers

•VRTX is the larger company ($112.92B vs $87.75B market cap).
•ELV trades at the lower earnings multiple (17.19 vs 26.39 P/E).
•VRTX converts more revenue to profit (35.40% vs 2.62% net margin).
•VRTX grew revenue faster over the past five years (13.82% vs 9.97% CAGR).
•ELV pays a dividend (1.70% yield) while VRTX does not currently pay one.

Which is better, ELV or VRTX?

Metric tally: ELV 7 · VRTX 9

It depends on what you're optimizing for:

ValueELV(lower P/E)

GrowthVRTX(faster 5Y revenue CAGR)

QualityVRTX(higher ROIC)

Valuation

Metric	ELV	VRTX
P/E ratio	17.19●	26.39
Forward P/E	13.82●	20.58
P/S ratio	0.44●	9.31
P/B ratio	2.03●	5.89
PEG ratio	2.58●	3.23
EV / EBITDA	12.48●	20.72
FCF yield	7.24%●	3.25%

Profitability

Metric	ELV	VRTX
Gross margin	23.16%	86.28%●
Operating margin	3.81%	38.97%●
Net margin	2.62%	35.40%●
ROE	11.94%	22.41%●
ROIC	6.65%	18.12%●

Dividends

Metric	ELV	VRTX
Dividend yield	1.70%	—
Payout ratio	27.24%	—

Growth (annualized)

Metric	ELV	VRTX
Revenue CAGR (5Y)	9.97%	13.82%●
EPS CAGR (5Y)	6.67%	8.17%●
FCF CAGR (5Y)	-7.76%	4.01%●
Total return CAGR (5Y)	2.50%	18.17%●

Frequently asked

Which is better, ELV or VRTX?: It depends on your goal. value: ELV (lower P/E); growth: VRTX (faster 5Y revenue CAGR); quality: VRTX (higher ROIC). Across all compared metrics, VRTX leads 9 to 7.
Is ELV or VRTX cheaper?: On trailing earnings, ELV is cheaper: ELV trades at a 17.19 P/E and VRTX at 26.39.
Which has grown faster, ELV or VRTX?: Over the past five years, VRTX grew revenue faster — ELV at a 9.97% CAGR versus VRTX at 13.82%.
Does ELV or VRTX pay a bigger dividend?: ELV pays a dividend (1.70% yield) while VRTX does not currently pay one.
Is ELV or VRTX more profitable?: VRTX runs the higher net margin — ELV at 2.62% versus VRTX at 35.40%.
Which has been the better investment, ELV or VRTX?: Over the past 10-year, VRTX delivered the higher annualized total return — ELV at 13.43% versus VRTX at 17.13%. Past performance doesn't predict future results.

Go deeper

Full ELV analysis Full VRTX analysis Interactive comparison tool

Dig into the metrics

Elevance Health P/E ratio Vertex Pharmaceuticals P/E ratio Elevance Health dividend yield Vertex Pharmaceuticals dividend yield Elevance Health ROE Vertex Pharmaceuticals ROE Elevance Health operating margin Vertex Pharmaceuticals operating margin Elevance Health revenue growth Vertex Pharmaceuticals revenue growth Elevance Health free cash flow Vertex Pharmaceuticals free cash flow

Elevance Health & Vertex Pharmaceuticals appear in these rankings

Highest ROIC Stocks Highest Operating Margin Stocks Highest FCF Yield Stocks Best 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 13, 2026.